Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.66 |
| ▸ | LMNA | P02545 | 3/20 | 0.66 |
| ▸ | MAPT | P10636 | 9/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.63 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.62 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | MITF | O75030 | 1/20 | 0.58 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 3/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11194107 | 0.85 | AKR1C3 (0.62) | ALDH1A1LMNAMAPTSMN1; SMN2AKR1C3 | |
| SCHEMBL29057437 | 0.83 | MAPT (0.68) | ALDH1A1LMNAMAPTSMN1; SMN2AKR1C3 | |
| SCHEMBL2074819 | 0.83 | MAPT (0.68) | ALDH1A1LMNAMAPTSMN1; SMN2AKR1C3 | |
| SCHEMBL27783156 | 0.83 | AKR1C3 (0.85) | ALDH1A1LMNAMAPTSMN1; SMN2AKR1C3 | |
| SCHEMBL1811704 | 0.82 | MAPT (0.63) | ALDH1A1LMNAMAPTSMN1; SMN2AKR1C3 | |
| Ammonia Solution, Strong SCHEMBL27607455 | 0.82 | MAPT (0.66) | ALDH1A1LMNAMAPTSMN1; SMN2AKR1C3 | |
| SCHEMBL1393155 | 0.81 | AKR1C3 (0.68) | ALDH1A1LMNAMAPTSMN1; SMN2AKR1C3 | |
| SCHEMBL6151230 | 0.80 | SIRT6 (0.81) | ALDH1A1LMNAMAPTSMN1; SMN2AKR1C3 | |
| SCHEMBL15271381 | 0.80 | SIRT6 (0.81) | ALDH1A1LMNAMAPTSMN1; SMN2AKR1C3 | |
| SCHEMBL3012718 | 0.80 | AKR1C3 (0.67) | ALDH1A1LMNAMAPTSMN1; SMN2AKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9452168-B2 | Pyrrole antifungal agents | F2G LTD (GB) | 2016-09-27 | — | — | US | disclosed |
| US-20150238500-A1 | PYRROLE ANTIFUNGAL AGENTS | F2G LTD (GB) | 2015-08-27 | — | — | US | disclosed |
| US-8993574-B2 | Pyrrole antifungal agents | F2G LTD (GB) | 2015-03-31 | — | — | US | disclosed |
| EP-2283006-B1 | PYRROLE ANTIFUNGAL AGENTS | F2G LTD (GB) | 2015-02-25 | — | — | EP | disclosed |
| EP-2626361-B1 | Pyrrole antifungal agents | F2G LTD (GB) | 2014-10-15 | — | — | EP | disclosed |
| EP-2626361-A1 | Pyrrole antifungal agents | F2G Limited (GB) | 2013-08-14 | — | — | EP | disclosed |
| US-20110152285-A1 | PYRROLE ANTIFUNGAL AGENTS | F2G LTD (GB) | 2011-06-23 | — | — | US | disclosed |
| EP-2283006-A1 | PYRROLE ANTIFUNGAL AGENTS | F2G Limited (GB) | 2011-02-16 | — | — | EP | disclosed |
| WO-2009130481-A1 | PYRROLE ANTIFUNGAL AGENTS | F2G LTD (GB) | 2009-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152285-A1 | PYRROLE ANTIFUNGAL AGENTS | FOXM1, PYCR1, ARG1 | ALDH1A1 219/4885LMNA 3641/4885MAPT 1696/4885 |
| US-20150238500-A1 | PYRROLE ANTIFUNGAL AGENTS | FOXM1, PYCR1, ARG1 | ALDH1A1 219/4885LMNA 3641/4885MAPT 1696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.